Keywords: Germany, IQWiG, AMNOG, Bristol-Myers, AstraZeneca, Komboglyze, Diabetes, Cell Therapeutics, Pxuvri, Non-Hodgkin lymphoma

Germany's IQWiG finds no added benefit for Komboglyze or for Pixuvri

Article | 04 March 2013

Print This

In an early benefit assessment under Germany’s Act on the Reform of the Market for Medicinal Products (AMNOG), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in